Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
How to get rid of your Christmas tree — and the 1 thing to never, ever do with it - 2Turkey’s intel chief lays out country’s vision for Middle East, world
- 3The Response to Fake General Knowledge: Investigating the Eventual fate of artificial intelligence
- 4Dominating the Art of Composing: Creator Bits of knowledge
- 5How will the universe end?
- Aurora chaser catches a fox basking in the glow of Finland's legendary 'fox fires' (photos)
- The Artemis II launch is tonight. Here's how to watch it live.
- The 10 Most Significant Virtual Entertainment Missions
- Former school bus aide pleads guilty to assaulting 3 autistic students in Colorado
- Instructions to Pick the Ideal Pre-assembled Home for Your Necessities
- Farewell, comet 3I/ATLAS! Interstellar visitor heads for the outer solar system after its closest approach to Earth
- Churches and politicians in South Sudan call for 'lasting peace' in Easter messages
- Vote In favor of Your Favored Kind Of Organic product
- 7 Powerful Techniques to Boost Efficiency with Your Cell Phone: A Thorough Aide
